A New Drug for Relapsed/Refractory Myeloma Patients: Melflufen
![A New Drug for Relapsed/Refractory Myeloma Patients: Melflufen image](https://healthtree.org/images-resize?width=1000&height=1000&imageUrl=https%253A%252F%252Fstorage.googleapis.com%252Fcrowdnews-media-library%252F605f432e-a347-4425-bb24-c6413fc6920e.png)
Event Description
A new treatment for multiple myeloma called melflufen (PEPAXTO®) was recently FDA-approved for relapsed or refractory multiple myeloma patients who have received at least four prior lines of therapy. Join us to hear Dr. Agne Paner of Rush University explain what the new therapy is, who qualifies for it, when it should be considered and how it works. Come with questions for the Q&A!
Schedule & Agenda
Speakers & Moderators
![The panelist Jennifer Ahlstrom](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/community%2Fpublic%2Fshared%2FJenny%20Bio%20300x300.jpg?alt=media)
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
![The panelist Agne Paner, MD](https://storage.googleapis.com/crowdnews-media-library/747628dd-33af-435f-a4f4-15439415bc4a.png)
Dr. Paner is an Associate Professor of Medicine in the Multiple Myeloma and Amyloidosis Program at Rush Medical College. Her research interests include clinical trials with innovative approaches to the treatment of patients with multiple myeloma and amyloidosis. She had hands-on experience in the HORIZON trial. She has been treating multiple myeloma for over 10 years and takes care of about 200 patients with multiple myeloma a year.
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
![newsletter icon](https://static.healthtree.org/icons/newsletter-icon.png)
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:
![Johnson and Johnson](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FJohnson%20&%20Johnson%20Logo_64b18f59-85c9-4c20-a5ff-3842e69d8066.jpg?alt=media)
![Sanofi](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FSanofi%20updated%202023_d25a8d12-4f09-410c-9eb1-1e725b0b7c3e.jpg?alt=media)
![Pfizer](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FPfizer%20Logo%202024_50ae4587-5fdc-48e2-9a52-21651c643494.png?alt=media)
![Genentech](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/admin%2Fpublic%2Fshared%2FGenentech_Logo-700x182_e3c64168-dcf4-4540-9e9d-26500b26920a.png?alt=media)
![Regeneron](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FRegeneron_dec43aa4-fe53-4d5a-9b7f-4170101b47f9.webp?alt=media)
![Adaptive](https://firebasestorage.googleapis.com/v0/b/healthtree-production.appspot.com/o/gallery%2Fpublic%2FAdaptive%20Logo%204.2023_e0d11d37-8b31-4c88-a0fc-4d07efc9b16b.png?alt=media)